Evaluation of cell-free DNA approaches for multi-cancer early detection

Cancer Cell. 2022 Dec 12;40(12):1537-1549.e12. doi: 10.1016/j.ccell.2022.10.022. Epub 2022 Nov 17.

Abstract

In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining clinical limit of detection (LOD) based on circulating tumor allele fraction (cTAF), enabling performance comparisons. Among 10 machine-learning classifiers trained on the same samples and independently validated, when evaluated at 98% specificity, those using whole-genome (WG) methylation, single nucleotide variants with paired white blood cell background removal, and combined scores from classifiers evaluated in this study show the highest cancer signal detection sensitivities. Compared with clinical stage and tumor type, cTAF is a more significant predictor of classifier performance and may more closely reflect tumor biology. Clinical LODs mirror relative sensitivities for all approaches. The WG methylation feature best predicts cancer signal origin. WG methylation is the most promising technology for MCED and informs development of a targeted methylation MCED test.

Keywords: CCGA; MCED; cancer screening; cfDNA; multi-cancer early detection; single nucleotide variants; somatic copy number alterations; whole-genome bisulfite sequencing; whole-genome methylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Cell-Free Nucleic Acids* / genetics
  • DNA Methylation
  • Early Detection of Cancer
  • Humans
  • Neoplasms* / diagnosis
  • Neoplasms* / genetics

Substances

  • Cell-Free Nucleic Acids
  • Biomarkers, Tumor